Antiplatelet therapy in patients who received percutenous coronary intervention with concomitant hihg-ischemic risk

24-month ticagrelor-based dual-antiplatelet threapy versus clopidogrel-based dual-antiplatelet theRapy aftEr 12 months of DrUg-eluting stent implantation in high isChEmic risk patients: P-REDUCE trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006445

Enrollment

3488

Registered

2021-08-13

Start date

2022-06-23

Completion date

Unknown

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The patients who will be enrolled for this trial are those with drug-eluting stent insertion 12 to 24 months before enrollment. Among them, the patients with presence of hihg-ischemic will be r

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age =50 years old 2. History of drug-eluting stent implantation due to acute myocardial infarction 12 to 24 months ago 3. High-risk for ischemic events (at least one of the following) 1) Age >65 years old 2) Medical treatments for diabetes mellitus 3) Multi-vessel coronary artery disease 4) More than 2 episodes of myocardial infarction 5) Chronic kidney disease (stage III or IV)

Exclusion criteria

Exclusion criteria: 1. Age =85 years old 2. Pregant women or women with potential childbearing 3. Life expectancy < 1 year 4. Inability to understand or read the informed consent 5. Need for long-term anticoagulation therapy

Design outcomes

Primary

Measure	Time frame
Composite of all-cause death, myocardial infarction, or stroke	—

Secondary

Measure	Time frame
BARC type 2, 3, or 5 bleeding	—

Countries

Korea, Republic of

Contacts

Public ContactSeung-Jun Lee

Yonsei University Health System, Severance Hospital

jh2709@gmail.com+82-2-2228-8460

Outcome results